Status:
COMPLETED
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenic Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this 6-week study is to determine whether treatment with Seroquel® Sustained Release (SR) is more effective than placebo in the treatment of acute schizophrenia. PLEASE NOTE: Seroquel ...
Eligibility Criteria
Inclusion
- To be considered for this study the patients should be aged between 18 to 65 years, need to suffer from schizophrenia and must be willing to participate.
Exclusion
- Patients that suffer from psychiatric disorders other than schizophrenia including drug abuse and dependence, or medical conditions such as specific kidney, heart or thyroid problems, and patients with a known lack of response to drugs for schizophrenia will not be considered for this study.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
535 Patients enrolled
Trial Details
Trial ID
NCT00206115
Start Date
November 1 2004
End Date
December 1 2005
Last Update
January 4 2013
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Burgas, Bulgaria
2
Research Site
Rousse, Bulgaria
3
Research Site
Sofia, Bulgaria
4
Research Site
Sofia- Novi Iskar, Bulgaria